Apnimed targets $608 million valuation in sleep apnea pill IPO

Apnimed Inc., a late-stage drug developer working on a once-daily pill for obstructive sleep apnea, is targeting a valuation of as much as $608 million in its US initial public offering, joining a wave of biotech companies returning to public markets after a prolonged drought that saw IPO volumes fall to their lowest in more than a decade.

The Cambridge, Massachusetts-based company plans to sell 10 million shares at $14 to $16 apiece, according to a regulatory filing Monday, aiming to raise up to $160 million. At the midpoint of the range, the offering would value Apnimed at roughly $540 million on a fully diluted basis. The deal is backed by Japanese pharmaceutical firm Shionogi & Co., which has invested in the company since its founding in 2017 and holds a significant pre-IPO stake that provides a strategic anchor, strengthening the offering's credibility with institutional investors.

"The IPO market for biotech has reopened meaningfully, and Apnimed's lead asset addresses a massive unmet need in sleep medicine," said Tom Brennan, IPO and M&A analyst at Edgen. "A successful listing at this valuation would signal that investors are willing to reward late-stage clinical assets with clear regulatory pathways and large addressable markets."

Apnimed's lead candidate, AD109, is a bedtime pill designed as an alternative to continuous positive airway pressure machines, the current standard of care for obstructive sleep apnea. The condition affects an estimated 30 million adults in the US alone, with many patients unable to tolerate CPAP therapy — adherence rates for CPAP drop below 50 percent within the first year, according to published studies. That compliance gap represents a commercial opportunity that Apnimed estimates could support peak annual sales exceeding $2 billion if AD109 gains regulatory approval.

The company intends to use proceeds from the IPO to fund the regulatory approval process, commercial launch preparations, and research into additional pipeline candidates. AD109 is currently in late-stage clinical trials, with pivotal data expected in the coming quarters. If results are positive, Apnimed could file for US Food and Drug Administration approval as early as 2027, putting it on track for a potential launch in 2028.

Biotech IPOs have rebounded after hitting their lowest level in more than a decade in 2025, when the Federal Reserve's elevated interest rates and broad risk aversion drove many early-stage companies to delay or abandon listing plans. The Renaissance IPO Index, which tracks newly public companies, has gained roughly 18 percent over the past 12 months as the Fed's rate-cutting cycle improved the financing environment for cash-burning drug developers. Apnimed's offering comes as investors increasingly seek exposure to companies with late-stage assets in large addressable markets rather than early-stage platforms with distant revenue horizons.

The last time a sleep-focused biotech went public in the US was in 2021, when Inspire Medical Systems, which makes an implanted nerve stimulator for sleep apnea, listed at a valuation of roughly $1.5 billion. Inspire shares have since more than doubled, providing a comparable that underwriters are likely to reference in marketing the Apnimed deal. The broader medtech and biotech IPO pipeline has also shown signs of life, with at least six other healthcare companies filing for US listings in the second quarter of 2026, according to data compiled by Bloomberg.

Apnimed faces competition from established players in the sleep apnea space, including ResMed Inc., which dominates the CPAP market with roughly $4.5 billion in annual revenue, and Eli Lilly & Co., which is developing its own sleep apnea treatment targeting the same patient population. The presence of large-cap competitors underscores both the size of the opportunity and the execution risk Apnimed will face if AD109 reaches the market. Shionogi's involvement provides Apnimed with a deep-pocketed partner that could support commercialization efforts, particularly in Asian markets where the Japanese drugmaker has an established presence.

BofA Securities, Evercore ISI, Cantor Fitzgerald and LifeSci Capital are underwriting the offering. The company plans to list its shares on the Nasdaq Global Market under the ticker APMD.

This article is for informational purposes only and does not constitute investment advice.